STEMEDICA OBTAINS AN EXCLUSIVE WORLDWIDE LICENSE FOR STEM CELL STABILIZATION AND PRESERVATION TECHNOLOGIES
Stemedica announced today that Universal Stabilization Technologies (UST) has granted to Stemedica subsidiary StemProtein, LLC, an exclusive worldwide license to its technology known as Preservation by Vaporization (PBV) for industrial scale stabilization of stem cells and stem cell derivatives.
STEMEDICA SECURES U.S. PATENT TO USE MULTIPLE STEM CELL LINES SIMULTANEOUSLY TO TREAT ISCHEMIC STROKE
Stemedica was issued a new patent entitled “Composition of Stem Cells and Stem Cell Factors for Their Use and Manufacture.” This patent covers a method for treating patients with ischemic stroke, and the treatment includes intrathecal administration of hypoxically grown neural stem cells and intravenous administration of hypoxically grown mesenchymal stem cells.More news >>
DRIVEN BY 30 YEARS OF STEM CELL RESEARCH & SCIENTIFIC ADVANCEMENT
Transforming Medicine for the 21st Century
Stemedica Cell Technologies, Inc., is transforming regenerative medicine through the development and manufacturing of adult ischemic-tolerant stem cell products and biological compounds. Our technology has led us to breakthroughs that are changing medicine and improving life globally. As one of the few companies licensed and approved for clinical grade manufacturing and trial applications by regulatory agencies worldwide, our focus is on producing the best-in-class products available today.
Watch a short informative video about our company and the unique technological advantages of our proprietary adult stem cells.
Unique stem cell-based products to treat dermatological diseases and improve the appearance of patients’ skin
The company is currently in clinical trials with therapies for photoaged skin. StemCutis is using stem cells and their factors to treat a range of conditions that affect skin and tissue appearance: compromised skin, diabetic ulcers, hair loss, burns and hypertrophic, hypotrophic and keloid scars.
Further information >>
Applying stem-cell technology for cardiovascular indications is not just an idea anymore.
CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication.
Further information >>